<DOC>
	<DOCNO>NCT00732641</DOCNO>
	<brief_summary>This study aim assess efficacy peginterferon α-2b , compare control arm receive maintenance treatment , adult subject multiple myeloma respond prior induction therapy . Peginterferon α-2b give weekly injection disease progression relapse , maximum 5 year ( whichever occurs first ) .</brief_summary>
	<brief_title>Peginterferon α-2b Maintenance Therapy Participants With Multiple Myeloma Who Responded Induction Therapy ( P01972-AM7 )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Must demonstrate willingness participate study adhere dose visit schedule Must ≤85 year age either sex , race Must stage II III multiple myeloma histological confirmation consistent diagnosis multiple myeloma ( biopsy osteolytic soft tissue tumour compose plasma cell bone marrow aspirate and/or biopsy demonstrate ≥ 10 % plasmacytosis ) . The histological confirmation obtain prior induction chemotherapy bone marrow transplant chemotherapy May receive prior interferon treatment multiple myeloma Must confirm he/she practice adequate contraception If female volunteer childbearing potential , must negative serum pregnancy test Screening/Visit 1 Must free clinically relevant disease ( multiple myeloma ) would , principal investigator 's and/or sponsor 's opinion , interfere conduct study study evaluation Must able adhere dose visit schedule Clinical laboratory test ( complete blood chemistry [ CBC ] , blood chemistry , urinalysis ) must consistent adequate hepatic renal function , define &lt; 2 time upper limit laboratory normal ( ULN ) adequate hematological function define platelet &gt; 50,000/mm^3 , Hemoglobin ≥9.0 g/dL , white blood count ( WBC ) count ≥2000/mm^3 Must complete , partial minimal response either one induction chemotherapy regimen one myelosuppressive chemotherapeutic treatment follow peripheral blood stem cell infusion first line treatment . Any type pretransplant chemotherapy condition regimen allow Performance Status Karnofsky score ≥60 % time randomization Is female pregnant , intend become pregnant study Is nurse , intend nursing study Has use investigational product within 30 day prior enrollment Have follow clinical condition : Pre exist psychiatric condition , especially depression , history severe psychiatric disorder , major psychosis , suicidal ideation and/or suicidal attempt . Subjects history mild depression may consider entry protocol provide pretreatment assessment subject 's mental status indicate subject clinically stable ongoing evaluation patient 's mental status study Central Nervous System ( CNS ) trauma active seizure disorder require medication Significant cardiovascular dysfunction within previous 6 month study start ( eg , angina , congestive heart failure , recent myocardial infarction , severe hypertension significant arrhythmia ) patient multigated acquisition ( MUGA ) echocardiogram &lt; 40 % ; History prior malignant disease within previous 5 year study start , except surgically cure squamous cell basal cell skin carcinoma Stage I cervical carcinoma cervical carcinoma situ ; Known severe coagulation disorder , thrombophlebitis pulmonary embolism decompensate liver disease ; Uncontrolled diabetes mellitus thyroid dysfunction ( responsive therapy ) ; Severe chronic pulmonary disease ( eg , chronic obstructive pulmonary disease ) ; Has active and/or uncontrolled infection Is situation condition , opinion investigator , may interfere optimal participation study Is participate clinical study Is staff , affiliate , family member staff personnel directly involve study Is allergic sensitivity study drug excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>